Revolution Medicines, Inc. Warrant

Revolution Medicines, Inc. is a clinical-stage precision oncology company that develops targeted therapies for RAS-addicted cancers. Its pipeline includes RAS(ON) inhibitors, such as daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are being evaluated as monotherapies and in combinations. The company was incorporated in 2014 and is headquartered in Redwood City, California.